Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- Details
- Category: HIV Treatment
- Published on Wednesday, 09 August 2017 00:00
- Written by Liz Highleyman
A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for 7 days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, researchers reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 09 August 2017 00:00
- Written by Roger Pebody
One of the first studies to explore the acceptability, safety, and use of pre-exposure prophylaxis (PrEP) in adolescents in an African context has found that PrEP was safe and tolerable, although PrEP usage and adherence did tail off during the 12 months of the program.
IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
- Written by Gus Cairns
A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.
IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
- Written by Liz Highleyman
A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.
PAS 2017: Many Doctors Wary of Providing PrEP for Young Patients
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
Only about a third of family practice and pediatric providers said they would be likely to prescribe HIV pre-exposure prophylaxis (PrEP) to adolescent patients, underlining the need to educate providers outside the HIV and sexually transmitted disease fields, according to a report at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.
More Articles...
- HIV PrEP Is Approved in Scotland
- BHIVA 2017: Large Fall in London HIV Diagnoses Is Due to Combination Prevention, Not Just PrEP
- CROI 2017: Bacterial Vaginosis Does Not Affect Efficacy of Oral PrEP in Women
- CROI 2017: STI Rates Among PrEP Users Are High, But Evidence that PrEP Increases Them Is Inconclusive
Web Design and Development by